Rewiring local immune milieu by boosting dendritic cell for pancreatic cancer treatment

Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model

Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer

Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model

Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma

Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients

Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1

Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer.

Effect of targeting CD40 for DC vaccination in pancreatic adenocarcinoma.